ARQ-092 is a selective inhibitor of the AKT kinase, a key protein involved in cell survival, growth, and proliferation pathways. It is primarily investigated for its potential in treating genetic disorders and cancers driven by mutations in the PI3K/AKT/mTOR signaling pathway. One major application is in the treatment of Proteus syndrome and other overgrowth disorders caused by AKT1 mutations, where ARQ-092 helps suppress abnormal cell growth. It has also shown promise in preclinical and clinical studies for cancers such as breast, ovarian, and glioblastoma, especially in tumors with hyperactive AKT signaling. Due to its targeted mechanism, ARQ-092 is being explored in combination therapies to enhance the efficacy of chemotherapy, radiation, or other targeted agents while minimizing damage to healthy cells.